News

FDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.

The first 2-dose hepatitis B vaccine, which was recently approved by FDA, is expected to be commercially available in early 2018.

FDA warns that this compounded eye drug could lead to a disease that causes blindness.

More education is needed for diabetic patients after a patient died from incorrectly using an insulin pen, according to a new warning from the Institute for Safe Medication Practices.

If it is approved by FDA, an investigational drug to improve glycemic control in patients with type 2 diabetes will likely be a strong competitor to Eli Lilly’s dulaglutide (Trulicity).

FDA approved the herpes zoster vaccine (Shingrix, GlaxoSmithKline) to treat shingles in adults aged 50 years and older.

Soon after President Donald Trump declared the opioid abuse crisis a “public health emergency," shareholder activist groups said they aim to hold drug manufacturers and distributors liable for their part in the crisis.

Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.

A new survey on genetic testing has surprisingly results on consumer acceptance and impact for healthcare executives.

A survey unveiled at the HealthCare Executive Group’s Annual Forum divulges surprising findings about healthcare technology and innovation.

We asked successful healthcare industry leaders to share their top tips for young executives. Here’s what they said.

A new survey from consumer health companies has revealing findings about American health and well-being.

Genetics and genomics are starting to have an impact on cardiovascular care. Here’s what payers should consider when deciding whether to cover a gene expression test.

A Kaiser Permanente study found that a new way to test for HPV has the potential to increase efficiency and decrease waste.

Here are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.

PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.

The Trump Administration issued two rules rolling back the federal requirement that employers include birth control coverage in their group health plans. Here’s what you need to know.

Two opioid use disorder drugs have been recommended for approval by FDA committees.

Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.

Widespread adoption of population-focused nursing practice will likely take place over the next five to 10 years. Here’s how to stay ahead of the curve.

New public opinion survey about opioid use from Prime Therapeutics has surprising results.

Moffitt Cancer Center expert shares her thinking on managing chemotherapy-related side effects.

Patients who lack resources likely won’t have improved health outcomes even with interventions. Some plans are exploring how to address the problem.

Education is a significant element of comprehensive care for COPD patients. In this Q&A, one expert shares her recommendations.

The CVS Health-Aetna potential merger will have healthcare executives rethinking traditional industry competitors. Here’s why.

Healthcare executives identify how the industry could be affected if the Aetna-CVS merger goes through.

As managed care leaders, better care for patients can be achieved through increased medical data exchange through diverse and collaborative organization involvement.

Is interoperability in healthcare a dream, or will payers, providers, and technology vendors finally come together to make data more available to one another?

High customer satisfaction has been linked with stronger loyalty, sales, and profits. So why hasn’t the healthcare industry caught on?